Post-Bariatric Hypoglycemia (PBH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Post-Bariatric Hypoglycemia (PBH) Market Outlook
Thelansis’s “Post-Bariatric
Hypoglycemia (PBH) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2024 To 2034" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Post-Bariatric
Hypoglycemia (PBH) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
Post-Bariatric Hypoglycemia (PBH)
Overview
Post-bariatric
hypoglycemia (PBH) occurs when patients undergoing various bariatric procedures
experience low blood glucose levels following meals. PBH is recognized as a
metabolic complication associated with different types of bariatric surgery
(BS). While BS is currently considered the most effective and relatively safe
treatment for obesity and its related complications, the development of PBH can
significantly impact patients’ quality of life. PBH is characterized by
postprandial hypoglycemic symptoms, typically occurring between one and four
hours after a meal, with a higher frequency observed one year post-surgery.
These symptoms are accompanied by low blood glucose levels, often confirmed
through provocative testing.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations
for target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment